bioAffinity Technologies, Inc. (BIAF)
NASDAQ: BIAF · Real-Time Price · USD
1.510
-0.150 (-9.04%)
At close: Dec 12, 2025, 4:00 PM EST
1.580
+0.070 (4.64%)
After-hours: Dec 12, 2025, 7:52 PM EST
bioAffinity Technologies Employees
bioAffinity Technologies had 57 employees as of December 31, 2024. The number of employees decreased by 18 or -24.00% compared to the previous year.
Employees
57
Change (1Y)
-18
Growth (1Y)
-24.00%
Revenue / Employee
$118,890
Profits / Employee
-$258,582
Market Cap
6.78M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 57 | -18 | -24.00% |
| Dec 31, 2023 | 75 | 61 | 435.71% |
| Dec 31, 2022 | 14 | 3 | 27.27% |
| Dec 31, 2021 | 11 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
BIAF News
- 10 days ago - bioAffinity Technologies' Noninvasive CyPath® Lung Test to Be Highlighted at American Cancer Society National Lung Cancer Roundtable - Business Wire
- 4 weeks ago - bioAffinity Technologies Reports Third Quarter 2025 Financial Results - Business Wire
- 5 weeks ago - bioAffinity Technologies Reports Accelerating Month-Over-Month Growth in CyPath® Lung Test Volume - Business Wire
- 6 weeks ago - bioAffinity Technologies Announces Acceptance of Australian Patent Application for Platform to Detect and Characterize Multiple Lung Diseases - Business Wire
- 7 weeks ago - bioAffinity Technologies Presents Research Supporting CyPath® Lung Processing Methods at CHEST 2025 - Business Wire
- 2 months ago - bioAffinity Technologies Announces Notification of Allowance for U.S. Patent Application for Its Diagnostic Algorithm and Test Method for Lung Cancer - Business Wire
- 2 months ago - bioAffinity Technologies Regains Compliance with Nasdaq Listing Requirements - Business Wire
- 2 months ago - WallachBeth Capital Announces The Closing of bioAffinity Technologies $1.8M Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules - PRNewsWire